title: [Evaluation on the safety and immunogenicity of Canada split influenza virus vaccine].
abstract: OBJECTIVE
  To evaluate the safety and immunogenicity of Canada split influenza virus vaccine.
  
  
  METHODS
  Cluster samples were by randomly chosen and divided into split vaccination group and homoimported influenza vaccination group.
  
  
  RESULTS
  After injection, fever-reaction and local reaction rates of 'trial' group were found as 3.69% and 1.75% respectively, but no statistical significance was found when compared with 'control' group. However the antibody positive rates of 'trail' and 'control' groupsappeared statistically significant (H1N1: 96.8% vs. 92.3%, H3N2: 95.8% vs. 90.2%, B: 52.3% vs. 62.3%). For geometric mean titer (GMT) of type H1N1, H3H2 and B antibody, 'trial' group and 'control' group increased 22.4, 16.8, 8.2 and 21.2, 12.5 and 7.4 times respectively. The antibody protective rates of type H1N1, H3N2 and B were 99%, 99% and 53.9% for 'trial' group, and 96.2%, 98.4% and 62.3% for 'control' but with no statistically significant difference.
  
  
  CONCLUSIONS
  Influenza split vaccine made in Shire company in Canada was safe and with good immunogenicity.
authors.affiliation: Jiangsu Provincial Center of Disease Control and Prevention, Nanjing 210009, China.
authors.forename: Yue-mei
authors.initials: YM
authors.lastname: Hu
authors.forename: Han-hua
authors.initials: HH
authors.lastname: Fang
authors.forename: Gui-hua
authors.initials: GH
authors.lastname: Gao
authors.forename: Xue-feng
authors.initials: XF
authors.lastname: Zhang
authors.forename: Yi-ju
authors.initials: YJ
authors.lastname: Zhang
authors.forename: Shi-wei
authors.initials: SW
authors.lastname: Zhu
authors.forename: Feng-cai
authors.initials: FC
authors.lastname: Zhu
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000917:Antibody Formation / Q000276:immunology; D002170:Canada; D002648:Child; D002675:Child, Preschool; D064420:Drug-Related Side Effects and Adverse Reactions / Q000276:immunology*; D005260:Female; D006801:Humans; D007223:Infant; D007267:Injections; D008297:Male; D008875:Middle Aged; D009975:Orthomyxoviridae / Q000276:immunology*; D013997:Time Factors; D014765:Viral Vaccines / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D055815:Young Adult
chemical_list: D014765:Viral Vaccines